Fabrice Piu Email Address

Senior Vice President, Research and Preclinical Development

Otonomy is a biotech and biopharmaceuticals company developing ear medicine and therapeutics to address unmet medical needs in the emerging otology market.

Biopharmaceutical company leader with over 15 years of industry experience. Key accomplishments include: establishing and leading productive and successful drug-discovery and preclinical development organizations, developing and advancing clinical candidates from early lead selection to market approval. Critical contributions to business development with successful partnering of drug-discovery technologies and platforms. Demonstrated expertise in various therapeutic area including otic, neurological, endocrinological and metabolic disorders. Key contributor to the development of: OTIPRIO, a FDA approved drug for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement, and the treatment of acute otitis externa in patients 6 months of age and older; Nuplazid, a FDA approved atypical antipsychotic drug indicated for the treatment of hallucinations and delusions associated with Parkinson's Disease.